Israel Englander Dyne Therapeutics, Inc. Transaction History

Millennium Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$13.06 - $29.18 $4.83 Million - $10.8 Million	-370,079 Reduced 95.36%	18,011 $511,000
Q4 2023 Feb 14, 2024	BUY	$6.62 - $13.64 $2.57 Million - $5.29 Million	388,090 New	388,090 $5.16 Million
Q1 2023 May 15, 2023	SELL	$10.88 - $15.0 $693,567 - $956,205	-63,747 Reduced 25.09%	190,363 $2.19 Million
Q4 2022 Feb 14, 2023	BUY	$9.37 - $13.8 $1.61 Million - $2.38 Million	172,159 Added 210.08%	254,110 $2.95 Million
Q3 2022 Nov 14, 2022	BUY	$7.2 - $15.17 $590,047 - $1.24 Million	81,951 New	81,951 $1.04 Million
Q1 2021 May 17, 2021	SELL	$14.0 - $29.3 $540,260 - $1.13 Million	-38,590 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$16.81 - $23.94 $2.61 Million - $3.72 Million	-155,475 Reduced 80.11%	38,590 $810,000
Q3 2020 Nov 16, 2020	BUY	$20.0 - $23.9 $3.88 Million - $4.64 Million	194,065 New	194,065 $3.92 Million

201

106M

82.7K

24.8K

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $1.69B
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.